Use of Long-acting Injectable Antipsychotic Drugs in the Elderly: A Retrospective Study.

IF 2.7 4区医学 Q3 NEUROSCIENCES

Clinical Psychopharmacology and Neuroscience Pub Date : 2026-05-31 Epub Date: 2025-10-29 DOI:10.9758/cpn.25.1320

Ayşe Nur İnci Kenar, Selin Balki Tekin

{"title":"Use of Long-acting Injectable Antipsychotic Drugs in the Elderly: A Retrospective Study.","authors":"Ayşe Nur İnci Kenar, Selin Balki Tekin","doi":"10.9758/cpn.25.1320","DOIUrl":null,"url":null,"abstract":"Objective: Despite the increasing use of long-acting injectable antipsychotics (LAIA) in the elderly population, there is still a lack of studies. This study aims to assess the treatment safety and tolerability of LAIAs in elderly patients.Methods: This retrospective study was conducted with patients over 60 years of age who were treated in the psychiatry clinic of a university hospital between 2014 and 2024 and underwent LAIA. Sociodemographic data, diagnoses, LAIA medications and side effects were obtained by accessing hospital records.Results: A total of 186 patients with a mean age of 70.20 (± 5.20) years were included in the study. The majority of patients were diagnosed with schizophrenia (53.2%), bipolar disorder (23.7%), and schizoaffective disorder (20.4%). The most commonly prescribed LAIA was paliperidone palmitate once-monthly 100 mg, with 19.9% of the patients. The most frequently used oral antipsychotic in combination with LAIA was olanzapine, used in 64 (34.2%) cases. No significant adverse effects related to the use of long-acting injectable drugs were observed.Conclusion: The utilisation of LAIAs in elderly patients appears to be both tolerable and safe. It can be considered for elderly patients suffering from chronic mental illness who are non-compliant with treatment.","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":"24 2","pages":"277-285"},"PeriodicalIF":2.7000,"publicationDate":"2026-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122152/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychopharmacology and Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.9758/cpn.25.1320","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Despite the increasing use of long-acting injectable antipsychotics (LAIA) in the elderly population, there is still a lack of studies. This study aims to assess the treatment safety and tolerability of LAIAs in elderly patients.

Methods: This retrospective study was conducted with patients over 60 years of age who were treated in the psychiatry clinic of a university hospital between 2014 and 2024 and underwent LAIA. Sociodemographic data, diagnoses, LAIA medications and side effects were obtained by accessing hospital records.

Results: A total of 186 patients with a mean age of 70.20 (± 5.20) years were included in the study. The majority of patients were diagnosed with schizophrenia (53.2%), bipolar disorder (23.7%), and schizoaffective disorder (20.4%). The most commonly prescribed LAIA was paliperidone palmitate once-monthly 100 mg, with 19.9% of the patients. The most frequently used oral antipsychotic in combination with LAIA was olanzapine, used in 64 (34.2%) cases. No significant adverse effects related to the use of long-acting injectable drugs were observed.

Conclusion: The utilisation of LAIAs in elderly patients appears to be both tolerable and safe. It can be considered for elderly patients suffering from chronic mental illness who are non-compliant with treatment.

查看原文本刊更多论文

老年人使用长效注射抗精神病药物：一项回顾性研究。

目的：尽管老年人使用长效注射抗精神病药物（LAIA）的情况越来越多，但仍缺乏相关研究。本研究旨在评估老年患者laas的治疗安全性和耐受性。方法：回顾性研究于2014 - 2024年在某大学附属医院精神科门诊就诊的60岁以上患者行LAIA治疗。通过查阅医院记录获得社会人口统计数据、诊断、LAIA药物和副作用。结果：共纳入186例患者，平均年龄70.20（±5.20）岁。大多数患者被诊断为精神分裂症（53.2%）、双相情感障碍（23.7%）和分裂情感障碍（20.4%）。最常用的LAIA处方是棕榈酸帕利哌酮每月一次100 mg，占19.9%。最常用的口服抗精神病药物是奥氮平，共64例（34.2%）。未观察到与使用长效注射药物相关的显著不良反应。结论：老年患者使用laas是可以耐受和安全的。对于患有慢性精神疾病的老年患者，如果不接受治疗，可以考虑使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY

CiteScore

4.70

自引率

12.50%

发文量

期刊介绍： Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.